Investor Relations News Releases News Releases January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version September 9, 2020 Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Additional Formats PDF Version August 12, 2020 Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version June 22, 2020 Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020 Additional Formats PDF Version June 8, 2020 Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th Additional Formats PDF Version May 29, 2020 Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity Additional Formats PDF Version May 14, 2020 Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020 Additional Formats PDF Version May 12, 2020 Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version May 4, 2020 Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020 Additional Formats PDF Version April 2, 2020 Phio Pharmaceuticals Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version March 31, 2020 Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version March 31, 2020 Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth Additional Formats PDF Version March 26, 2020 Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update Additional Formats PDF Version March 10, 2020 Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene Additional Formats PDF Version February 13, 2020 Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering Additional Formats PDF Version February 11, 2020 Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering Additional Formats PDF Version February 10, 2020 Phio Pharmaceuticals Announces Compliance with Nasdaq Listing Requirements Additional Formats PDF Version February 6, 2020 Phio Pharmaceuticals Announces Closing of $1.74 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version February 5, 2020 Phio Pharmaceuticals Announces $1.74 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version January 14, 2020 Phio Pharmaceuticals Announces Reverse Stock Split Additional Formats PDF Version Print Page Email Page RSS Feeds Email Alerts IR Contact Share
Investor Relations News Releases News Releases January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version September 9, 2020 Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Additional Formats PDF Version August 12, 2020 Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version June 22, 2020 Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020 Additional Formats PDF Version June 8, 2020 Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th Additional Formats PDF Version May 29, 2020 Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity Additional Formats PDF Version May 14, 2020 Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020 Additional Formats PDF Version May 12, 2020 Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version May 4, 2020 Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020 Additional Formats PDF Version April 2, 2020 Phio Pharmaceuticals Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version March 31, 2020 Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version March 31, 2020 Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth Additional Formats PDF Version March 26, 2020 Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update Additional Formats PDF Version March 10, 2020 Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene Additional Formats PDF Version February 13, 2020 Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering Additional Formats PDF Version February 11, 2020 Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering Additional Formats PDF Version February 10, 2020 Phio Pharmaceuticals Announces Compliance with Nasdaq Listing Requirements Additional Formats PDF Version February 6, 2020 Phio Pharmaceuticals Announces Closing of $1.74 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version February 5, 2020 Phio Pharmaceuticals Announces $1.74 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version January 14, 2020 Phio Pharmaceuticals Announces Reverse Stock Split Additional Formats PDF Version Print Page Email Page RSS Feeds Email Alerts IR Contact Share
News Releases January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version September 9, 2020 Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Additional Formats PDF Version August 12, 2020 Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version June 22, 2020 Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020 Additional Formats PDF Version June 8, 2020 Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th Additional Formats PDF Version May 29, 2020 Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity Additional Formats PDF Version May 14, 2020 Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020 Additional Formats PDF Version May 12, 2020 Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version May 4, 2020 Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020 Additional Formats PDF Version April 2, 2020 Phio Pharmaceuticals Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version March 31, 2020 Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version March 31, 2020 Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth Additional Formats PDF Version March 26, 2020 Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update Additional Formats PDF Version March 10, 2020 Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene Additional Formats PDF Version February 13, 2020 Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering Additional Formats PDF Version February 11, 2020 Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering Additional Formats PDF Version February 10, 2020 Phio Pharmaceuticals Announces Compliance with Nasdaq Listing Requirements Additional Formats PDF Version February 6, 2020 Phio Pharmaceuticals Announces Closing of $1.74 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version February 5, 2020 Phio Pharmaceuticals Announces $1.74 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version January 14, 2020 Phio Pharmaceuticals Announces Reverse Stock Split Additional Formats PDF Version
January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version
November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version
November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version
November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version
October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version
September 9, 2020 Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Additional Formats PDF Version
August 12, 2020 Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version
June 22, 2020 Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020 Additional Formats PDF Version
June 8, 2020 Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th Additional Formats PDF Version
May 29, 2020 Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity Additional Formats PDF Version
May 14, 2020 Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020 Additional Formats PDF Version
May 12, 2020 Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version
May 4, 2020 Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020 Additional Formats PDF Version
April 2, 2020 Phio Pharmaceuticals Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version
March 31, 2020 Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version
March 31, 2020 Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth Additional Formats PDF Version
March 26, 2020 Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update Additional Formats PDF Version
March 10, 2020 Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene Additional Formats PDF Version
February 13, 2020 Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering Additional Formats PDF Version
February 11, 2020 Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering Additional Formats PDF Version
February 10, 2020 Phio Pharmaceuticals Announces Compliance with Nasdaq Listing Requirements Additional Formats PDF Version
February 6, 2020 Phio Pharmaceuticals Announces Closing of $1.74 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version
February 5, 2020 Phio Pharmaceuticals Announces $1.74 Million Registered Direct Offering Priced At-the-Market Additional Formats PDF Version
